LAKE FOREST, CA -- (Marketwire) -- 09/29/09 -- CryoPort, Inc. (OTCBB: CYRX) today announced that it has recently received recognition by well known independent technology analyst group Forrester Research for the development of CryoPort Express Portal, the industry's first integrated logistics solution for shipping, tracking and monitoring of high-value biological specimens.

According to the September 2009 report titled "Case Study: CryoPort Turns to Cloud Computing to Develop Tomorrow's New Vaccines," the software developed by KLATU Networks and deployed on a public infrastructure-as-a-service (IaaS) leverages Amazon's EC2 cloud platform and delivers cost efficiency and on-demand scalability when it is needed. The solution integrates shipping logistics and temperature monitoring into a single application. It orchestrates data entry of multi-legs shipments, prepares FDA/Customs forms and shipping labels, and electronically transmits all the shipping data to the overnight courier for processing. During shipment, the system captures detailed temperature logs and monitors each leg of the shipment, stitching together multiple tracking numbers so that it looks to the end customer like one transaction.

Larry Stambaugh, CEO of CryoPort, stated, "Having such an esteemed group acknowledge the technological advancement we have made in the shipping and tracking of temperature sensitive materials becomes a major selling tool for the company. Third party recognition of our technology will only enhance our ability to promote this service."

Rick Kriss, CEO of KLATU Networks, said, "Working with CryoPort, we saw a perfect partnership opportunity to leverage our experience in wireless cryogenic freezer monitoring and Web 2.0 technologies. We spent a lot of time researching available solutions and looking at what it would take to change the game from the end-customers perspective."

About CryoPort, Inc.

CryoPort (www.cryoport.com) is commercializing proprietary, technology-driven shipping products for use in the rapidly growing global biotechnology and biopharmaceutical cold chain. The products developed by CryoPort are essential components of the infrastructure required for the clinical testing, research and end user deliver of temperature-sensitive medicines and biomaterials in an increasingly complex logistical environment.

SAFE HARBOR

This press release contains forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.